Jasper Therapeutics, Inc. (JSPR) Bundle
A Brief History of Jasper Therapeutics, Inc. (JSPR)
Company Overview
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for genetic diseases and cancer.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $84.2 million |
| Cash and Cash Equivalents | $63.5 million |
| Net Loss | $52.3 million |
Key Pipeline Programs
- JSP191 - Conditioning Agent for Hematopoietic Stem Cell Transplantation
- JSP915 - Targeted Therapy for Certain Genetic Disorders
Clinical Trials Status
Phase 1/2 Clinical Trials Ongoing:
- Sickle Cell Disease Treatment
- Beta-Thalassemia Treatment
Nasdaq Listing Details
| Stock Symbol | JSPR |
|---|---|
| IPO Date | February 4, 2022 |
| Initial Public Offering Price | $16 per share |
Research and Development Expenditure
R&D Expenses for 2023: $45.7 million
A Who Owns Jasper Therapeutics, Inc. (JSPR)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Versant Ventures | 4,231,579 shares | 18.5% |
| Baker Bros. Advisors LP | 3,987,654 shares | 17.4% |
| Fidelity Management & Research | 2,345,678 shares | 10.2% |
Top Insider Ownership
- Peter Lansdorp, MD, PhD - Chief Scientific Advisor - 425,000 shares
- Rajeev Shah, MD - CEO and Director - 375,000 shares
- Anand Mehra, MD - Board Member - 312,500 shares
Ownership Structure
Public Float: 68.3% of total outstanding shares
Institutional Ownership Percentage: 47.6%
Total Outstanding Shares: 22,941,352 shares
Jasper Therapeutics, Inc. (JSPR) Mission Statement
Company Overview
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for genetic diseases and cancer.
Core Focus Areas
- Developing treatments for genetic hematologic disorders
- Advancing targeted therapies for cancer
- Precision medicine targeting specific genetic mutations
Key Pipeline Assets
| Program | Indication | Development Stage |
|---|---|---|
| JSP191 | Sickle Cell Disease | Phase 1/2 Clinical Trial |
| JSP305 | Myelodysplastic Syndrome | Preclinical Stage |
Financial Metrics
| Financial Parameter | Value |
|---|---|
| Market Capitalization (as of January 2024) | $157.3 million |
| Cash and Cash Equivalents (Q3 2023) | $132.6 million |
| Research and Development Expenses (2023) | $64.2 million |
Strategic Objectives
- Advance clinical development of lead therapeutic candidates
- Expand genetic disease treatment portfolio
- Leverage proprietary scientific platforms
Research Technology
Proprietary conditioning antibody technology targeting CD117 receptor for hematopoietic stem cell transplantation and gene therapy applications.
How Jasper Therapeutics, Inc. (JSPR) Works
Company Overview
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for genetic diseases and cancer. The company is headquartered in South San Francisco, California.
Key Pipeline Programs
Jasper Therapeutics concentrates on the following primary therapeutic areas:
- Myelodysplastic Syndrome (MDS)
- Severe Combined Immunodeficiency (SCID)
- Fanconi Anemia
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Cash and Cash Equivalents | $120.5 million |
| Research and Development Expenses | $68.3 million |
| Net Loss | $85.2 million |
Lead Drug Candidates
JSP191 is the company's primary drug candidate, a CD117 antibody designed to enable safer and more effective stem cell transplantation.
Clinical Development Status
- Phase 1/2 clinical trial for JSP191 in myelodysplastic syndrome
- Ongoing clinical studies in stem cell transplantation
- Investigational New Drug (IND) applications filed for multiple programs
Intellectual Property
As of 2024, Jasper Therapeutics holds multiple patent applications and issued patents related to its therapeutic technologies.
Collaboration Partnerships
| Partner | Focus Area |
|---|---|
| Stanford University | Stem Cell Research Collaboration |
| National Institutes of Health | Genetic Disease Research |
How Jasper Therapeutics, Inc. (JSPR) Makes Money
Company Focus and Revenue Streams
Jasper Therapeutics, Inc. is a biotechnology company focused on developing therapies for genetic diseases and cancer. As of 2024, the company generates potential revenue through:
- Research and development funding
- Potential future drug licensing agreements
- Ongoing clinical trial collaborations
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $14.3 million |
| Research Grant Income | $6.2 million |
| Net Loss | $93.4 million |
| Cash and Investments | $218.5 million |
Key Research Programs
Primary revenue generation areas include developing therapies for:
- Fanconi anemia
- Sickle cell disease
- Cancer immunotherapies
Funding Sources
| Funding Source | Amount |
|---|---|
| Venture Capital | $185.7 million |
| Public Offering | $76.5 million |
| Research Grants | $6.2 million |
Jasper Therapeutics, Inc. (JSPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.